Blood
Articles in this Issue
Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003
Abstract Background: Despite progress in the treatment of diffuse large B cell lymphoma (DLBCL),outcomes for patients with relapsed/refractor...
Peripheral plasmablast expansion as a predictor and therapeutic target in chronic GVHD
Abstract Chronic GVHD (cGVHD) following allogeneic stem cell transplantation (allo-SCT) is marked by disruption of the adaptive immune syste...
Association between body composition analysis and clinical characteristics in diffuse large B-cell lymphoma
Abstract Background: Diffuse Large B-cell Lymphoma (DLBCL), the most prevalent aggressive subtype of Non-Hodgkin Lymphom...
BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma
Abstract Introduction: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory mu...
Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion
Abstract Background The prognosis of relapsed or refractory systemic diffuse large B-cell lymphoma (R/R DLBCL) is poor. Furthermore, the outc...
Novel protective role of factor XII in kidney ischemia/reperfusion injury in a rat model
Abstract Renal ischemia/reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI) that often leads to rapid and severe renal...
Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma
Abstract Patients with relapsed or refractory multiple myeloma (R/R MM) have a poor prognosis after failing standard treatments, including p...
Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial
Abstract Background: Total Metabolic Tumor Volume (TMTV) and β2-microglobulin (B2M) are established prognostic biomarkers in follicular lymp...
Comprehensive genomic profiling of diffuse large B cell lymphoma using targeted NGS: Insights into MYC, BCL2, and BCL6 rearrangements and beyond
Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) harbors recurrent gene rearrangements, particularly involving MYC, BCL2, and BCL...
Expanding access in pediatrics: Outcomes of haploidentical transplantation with reduced intensity and peripheral blood stem cells
Abstract Introduction: The growing complexity of health systems limits equitable access to hematopoietic stem cell transplantation (HSCT). T...
Comparative epidemiological analysis of hematological malignancies in adolescents and young adults (AYA) in the United States of America (USA), 1990–2021, with projections to 2040
Abstract Introduction: Adolescents and young adults (AYA), defined as individuals aged 15-39 years, represent a unique p...
Intracellular iron levels alter the protein interactome of PCBP1
Abstract Background: Iron is essential for cellular function. Homeostasis of iron is controlled post-transcriptionally via highly conserved...
The first characterization of disease burden and healthcare resource utilization for the recent definition of severe von Willebrand disease using a large United States real-world dataset
Abstract Introduction: von Willebrand Disease (VWD) is a heterogenous condition with variable manifestations of symptoms ranging from mild t...
Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T)
Abstract Background: Conventional allogeneic hematopoietic stem cell therapy (alloHSCT) is associated with increased toxicity and infections...
Real-world outcomes of epcoritamab in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) following CAR T-cell therapy: A multicenter retrospective study from the trinetx global network
Abstract Background: Epcoritamab (EPCO), a CD3xCD20 bispecific antibody, has emerged as a promising therapy for patients with relapsed/refra...
An exploratory analysis of health-related quality of life measures with belantamab mafodotin in combination with pomalidomide and dexamethasone (BPd) in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in dreamm-8
Abstract Introduction: Health-related quality of life (HRQOL) can be significantly impaired in patients with RRMM due to disease symptoms an...
Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression
Abstract Introduction Multiple Myeloma (MM) precursors Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Mye...
Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells
Abstract Background: Myeloproliferative neoplasms in accelerated or blast phase (MPN-AP/BP) are associated with a median...
Transcriptomic analysis identifies lipid metabolism signature of defective erythropoiesis in diamond blackfan anemia syndrome
Abstract Background: Diamond Blackfan anemia syndrome (DBAS) is a heterogeneous genetic disorder mainly caused by de novo heterozygous riboso...
Low dose of IL-2 application for graft-versus-host disease prophylaxis following haploidentical stem cell transplantation
Abstract Graft-versus-host disease (GVHD) are still major obstacles of haploidentical hematopoietic stem cell transplantation (haplo-HSCT)....
Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital
Abstract Background CEBPA-mutated (CEBPAmu) AML, particularly double mutations (CEBPAdm) or those involving the bZIP domain, is classified a...
The novel allosteric NEK7 inhibitor ofirnoflast (HT-6184) demonstrates robust and sustained hematologic response in subjects with IPSS-R very low, low or intermediate risk myelodysplastic syndrome (MDS) and symptomatic anemia
Abstract Introduction With few exceptions, current MDS therapeutics are not effective across all subsets of the disease and none address the...
Real-world outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia treated with IDH1 and IDH2 inhibitors in the frontline setting
Abstract Introduction: Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations occur in 3-5% of patients with myelodysplastic syndrome (MDS). Sel...
Impact of whole blood amustaline pathogen inactivation on plasma coagulation factor activity; Mechanism of action
Abstract Amustaline (S-303, 200 µM) in combination with glutathione (GSH) quencher inactivates pathogens in red blood cell concentrates with...
Outcomes of venous thromboembolism in multiple myeloma: A nationwide analysis of anticoagulation strategies
Abstract Background Multiple Myeloma (MM) has an increased risk of venous thromboembolism (VTE) involving the disease-re...